Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of 99mTc-3PRGD2 in Healthy Volunteers
NCT03974685Phase 1Completed
- Sponsor
- RDO Pharm
- Start
- Dec 2018
- Primary completion
- Jan 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 99mTc-3PRGD2 in lung cancer and breast cancer, sponsored by RDO Pharm. Primary endpoints: AUC(0-t), Percentage of Injected Dose in Urine and 3 more. Started Dec 2018; status: completed.
02
Drugs
99mTc-3PRGD2
03
Conditions
lung cancerbreast cancer
Beyond the preview
Go deeper on NCT03974685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03974685.